Jennifer Barrett, Associate Editor

Administered through a drug-eluting implant, islatravir demonstrated protection against HIV for up to 12 months.

In a Specialty Pharmacy Times® Insights video series, experts Atul A. Deodhar, MD, and Hillary Norton, MD, discussed clinical best practices surrounding the diagnosis, management, and treatment of AxSpA, including an overview of available therapies.

A Bluetooth-enabled, nanochannel drug delivery system administers controlled doses based on patients’ therapeutic needs.

Pre-symptomatic infants with spinal muscular atrophy treated with nusinersen showed continuous improvement in achieving motor milestones.

New study demonstrates a novel approach of linking HER2-targeting antibodies with chemotherapy drugs for patients with breast cancer.

Patients with psoriasis reported frequent use of complementary and alternative treatments when their initial therapies did not help or had adverse effects.

A new study of patients treated with ophthalmology medications indicates that electronic health records may not contain accurate, up-to-date information.

Selinexor (Xpovio, Karyopharm) tablets in combination with the corticosteroid dexamethasone was approved under the agency's accelerated approval program.

Pfizer’s bevacizumab-bvzr (Zirabev) demonstrated clinical equivalence and no clinically meaningful differences compared with the reference product.

Daratumumab (Darzalex, Janssen) is indicated for use in combination with lenalidomide and dexamethasone for patients with newly-diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.

Eculizumab (Soliris) is indicated for adult patients with neuromyelitis optica spectrum disorder who are anti-aquaporin-4 antibody positive.

An independent review of pharmacy benefit managers (PBMs) in Ohio indicates that PBM pricing practices likely contribute to rising health care costs.

This approval expands tezacaftor/ivacaftor’s indication to include patients ages 6 and older with cystic fibrosis who have certain genetic mutations.

Pembrolizumab is already an established treatment option for non-small cell lung cancer, with several approved indications for its use in the disease.

Popular brand-name prescription drugs have seen substantial price increases over the past 6 years, a trend that is likely to continue.

An abstract presented at the 2019 American Society of Clinical Oncology Annual Meeting showed end-of-study analysis results of the phase 3 CLEOPATRA trial.

The study evaluated the activity and tolerability of venetoclax combined with cytarabine or cytarabine/idarubicin in pediatric patients with relapsed/refractory acute myeloid leukemia.

Valoctocogene roxaparvovec (BioMarin) met pre-specified criteria for Factor VIII activity levels treating severe hemophilia A in a phase 3 clinical trial.

Gilteritinib (Xospata, Astellas Pharma) is indicated for adults with relapsed/refractory acute myeloid leukemia with an FMS-like tyrosine kinase 3 mutation.

The approval of R2 is based on data from the phase 3 AUGMENT study evaluating the safety and efficacy of the combination regimen compared with rituximab plus placebo in patients with previously-treated FL and MZL.

Genomic data may improve the selection of more precise models for metastatic breast cancer research.

Using real-time data helped providers identify racial disparities in cancer treatment and narrow the gap in treatment completion rates between white and black patients.

Statins can benefit patients with secondary progressive multiple sclerosis for reasons unrelated to their cholesterol-lowering effects.

Bruce Feinberg, DO, vice president and chief medical officer of Cardinal Health Specialty Solutions, recently explored both sides of the debate as to whether these tools are effective for managing costs or add barriers to patient access.

In a Specialty Pharmacy Times® Practice Pearls video series, expert panelists convened to discuss the challenges and best practices for dispensing multiple myeloma medications.

An analysis showed short-term health plans can expose enrollees to significant out-of-pocket costs for serious illnesses, such as cancer.

Risdiplam showed continued improvements in motor milestones and functions for patients with spinal muscular atrophy.

Pomalidomide (Pomalyst, Celgene) showed clinical benefit in patients with Kaposi sarcoma, regardless of HIV status.

From 2018 to 2040, the number of patients who will need chemotherapy each year is estimated to rise from 9.8 million to 15 million.

New data show that higher exposure to ocrelizumab (Ocrevus, Genentech) correlated with lower B-cell levels and lower rates of disability progression.